Gujarat approves incentives for Jambusar bulk drug park to cut API import dependence
Synopsis
Gujarat has formalised a comprehensive incentive package — including a 10% capital subsidy, decade-long utility reimbursements, and full stamp duty waiver — for pharma manufacturers at the 2,015-acre Jambusar Bulk Drug Park. The move is a direct policy response to India's long-running dependence on Chinese API imports, a vulnerability the pandemic made impossible to ignore.
Key Takeaways
The Gujarat government has approved a special incentive scheme for the Jambusar Bulk Drug Park in Bharuch district .
Key incentives include a 10 per cent capital subsidy on eligible fixed capital investment and 100 per cent reimbursement of stamp duty and registration fees on first land allotment.
Utility charges — covering power, steam, water, effluent treatment, and logistics — will be reimbursed for up to 10 years .
The park spans approximately 2,015 acres and will feature more than 10 common infrastructure facilities , including a CETP, solvent recovery units, and a Centre of Excellence.
The project targets domestic production of APIs , KSMs , and drug intermediates to reduce India's import dependence, particularly from China.
Thousands of skilled and semi-skilled jobs are expected to be generated, aligned with the Atmanirbhar Bharat and Viksit Bharat @2047 goals.
The Gujarat government has approved a special incentive scheme for pharmaceutical manufacturers setting up production units at the proposed Jambusar Bulk Drug Park in Bharuch district, offering a 10 per cent capital subsidy, reimbursement of utility charges for up to 10 years, and full reimbursement of stamp duty and registration fees on the first allotment of land. The move is aimed at strengthening domestic pharmaceutical manufacturing and reducing India's dependence on imports of Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and drug intermediates critical to medicine production.
About the Jambusar Bulk Drug Park
The park is being developed across approximately 2,015 acres in Jambusar, Bharuch district, in alignment with the Centre's national initiative to establish dedicated bulk drug parks and deepen domestic manufacturing capabilities. The facility is designed as a plug-and-play infrastructure ecosystem, featuring more than 10 common infrastructure facilities intended to significantly reduce both capital and operating costs for manufacturers.
These shared facilities include a Common Effluent Treatment Plant (CETP), a CSTP, a steam generation and distribution network, solvent recovery units, a Treatment, Storage and Disposal Facility (TSDF), deep-sea disposal infrastructure, a Centre of Excellence, and a multimodal logistics network. This integrated approach is designed to make the park attractive even for smaller manufacturers who may otherwise struggle with standalone infrastructure costs.
Key Incentives on Offer
Investors setting up at the park can choose between two policy frameworks: the dedicated Bulk Drug Park Scheme or the Viksit Gujarat Industrial Policy-2026, depending on their project scale and requirements. Under the dedicated scheme, manufacturers are eligible for a 10 per cent capital subsidy on eligible fixed capital investment (eFCI). Eligible micro, small and medium enterprises (MSMEs) can additionally avail special interest subsidies.
The scheme also covers reimbursement of utility charges for up to 10 years, encompassing expenses related to power, steam, water, effluent treatment, solid waste management, warehousing, and park maintenance. Separately, investors will receive 100 per cent reimbursement of stamp duty and registration fees on the first-time allotment of land within the park — a meaningful cost reduction at the project inception stage.
Strategic Rationale and National Context
India's pharmaceutical industry — the world's third-largest by volume — has long faced a structural vulnerability: heavy dependence on China for APIs and KSMs. This dependence was sharply exposed during the COVID-19 pandemic, prompting the Centre to launch a national bulk drug parks scheme with financial support to states. Gujarat's Jambusar park is one of the parks emerging under that umbrella programme.
Officials stated that the initiative is aligned with Prime Minister Narendra Modi's vision of 'Atmanirbhar Bharat' and 'Viksit Bharat @2047'. By expanding domestic production of critical pharmaceutical ingredients and intermediates, the project is intended to strengthen India's position in the global pharmaceutical supply chain and reduce reliance on overseas suppliers.
Expected Economic and Employment Impact
The Gujarat government expects the Jambusar park to leverage the state's established industrial base, coastal location, and logistics connectivity to attract substantial pharmaceutical investment. The project is projected to generate employment for thousands of skilled and semi-skilled workers, according to state officials. This comes amid broader efforts by multiple Indian states to capture a larger share of global pharmaceutical manufacturing as supply chains are restructured away from single-source dependencies.
With incentive guidelines now in place, the focus will shift to securing anchor investors and operationalising the common infrastructure facilities that will determine the park's long-term competitiveness.
Point of View
But the real test lies in execution speed and anchor investor attraction. India has announced multiple bulk drug park initiatives since 2020; the pace of operationalising common infrastructure — particularly effluent treatment and deep-sea disposal — has historically lagged timelines. The Jambusar park's plug-and-play promise is credible only if those facilities are ready before manufacturers are asked to commit capital. More broadly, reducing API import dependence requires not just new parks but competitive pricing relative to Chinese suppliers, who benefit from scale and state subsidies that India's individual state-level schemes cannot easily match without coordinated central procurement support.
NationPress
29 Oct 2026
Frequently Asked Questions
What is the Jambusar Bulk Drug Park in Gujarat?
The Jambusar Bulk Drug Park is a pharmaceutical manufacturing zone being developed across approximately 2,015 acres in Jambusar, Bharuch district, Gujarat. It is part of the Centre's national initiative to establish dedicated bulk drug parks and reduce India's dependence on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs).
What incentives is the Gujarat government offering at the Jambusar park?
Manufacturers setting up at the Jambusar Bulk Drug Park are eligible for a 10 per cent capital subsidy on eligible fixed capital investment, reimbursement of utility charges for up to 10 years, and 100 per cent reimbursement of stamp duty and registration fees on the first allotment of land. MSMEs can additionally avail special interest subsidies.
Why is India setting up bulk drug parks?
India's pharmaceutical industry depends heavily on imports — primarily from China — for APIs and KSMs used in medicine production. This dependence was exposed sharply during the COVID-19 pandemic, prompting the Centre to establish dedicated bulk drug parks to build domestic manufacturing capacity and reduce supply chain vulnerabilities.
What infrastructure will the Jambusar park provide?
The park will offer a plug-and-play ecosystem with more than 10 common infrastructure facilities, including a Common Effluent Treatment Plant, a CSTP, steam generation and distribution, solvent recovery, a Treatment Storage and Disposal Facility, deep-sea disposal infrastructure, a Centre of Excellence, and a multimodal logistics network.
Who can invest in the Jambusar Bulk Drug Park?
Pharmaceutical manufacturers, including MSMEs, can invest in the Jambusar park. Investors may choose between the dedicated Bulk Drug Park Scheme and the Viksit Gujarat Industrial Policy-2026 based on their project requirements, with both frameworks offering distinct financial incentives.
